Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Faced With Criticism, Bayh Dole-like Act At Bay In India; Government Takes Up Closer Scrutiny (Part 1 of 2)

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Patenting of public-funded research for innovation - an idea mooted a few years ago by India's former science and technology minister Kapil Sibal reflecting mostly from the Bayh-Dole Act in the U.S. - is now pending scrutiny by the Parliamentary Standing Committee before enactment but in its two-year-long run up has unobtrusively created a deep divide among the rank and file of the Indian pharmaceutical industry

You may also be interested in...



Faced With Criticism, Bayh Dole-like Act "At Bay" In India; Government Takes Up Closer Scrutiny (Part 2 of 2)

MUMBAI - Patenting of public-funded research for innovation is now pending scrutiny by India's Parliamentary Standing Committee and has created a deep divide among the rank and file of the Indian pharmaceutical industry. Part one of this story questioned whether such a bill could logistically fit with India's present regulatory structure. In this second part, PharmAsia News interviews different sources on both sides of the divide on this Indian version of the Bayh-Dole Act in the U.S

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

LL1132247

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel